
Japanese encephalitis
Japanese encephalitis is a potentially deadly infectious disease found mainly in Asia, where 100 000 clinical cases are estimated to occur each year. (1)Key facts
- Japanese encephalitis (JE) is the most common vaccine-preventable cause of encephalitis in Asia with estimated 100 000 clinical cases each year.(1,2)
- JE is endemic in 25 countries in Asia and the Western Pacific.(3)
- Japanese encephalitis virus (JEV) is transmitted to humans through bites from infected mosquitoes of the Culex species (mainly Culex tritaeniorhynchus).(1)
- JEV-infection can result in febrile illness or neurologic disease, including meningitis or encephalitis.(4)
- The case-fatality rate can be as high as 30% among those with disease symptoms.(1.2)
- Among survivors, 30%–50% have serious neurologic, cognitive, or psychiatric sequelae.(1.2)
- There is currently no antiviral treatment for JE.(1.2)
- Travelers should take further precautions to avoid mosquito bites. Personal preventive measures include the use of mosquito repellents and wearing long-sleeved clothing.(1,2)
- The Austrian vaccination schedule recommends vaccination for travelers to endemic areas of Asia.(5)
- Before traveling, check possible preventive measures. The platform www.reisemedizincheck.at can help you find a travel medicine expert in your area.
What is JE?
Japanese encephalitis (JE) is a potentially serious disease, which is caused by the Japanese-Encephalitis-virus, a mosquito-borne Flavivirus, and is closely related to dengue, yellow fever and West Nile viruses.(1)
JE is the main cause of viral encephalitis in Asia.(1)
JEV is transmitted to humans through the bites from infected mosquitoes of the Culex species (mainly Culex tritaeniorhynchus).(1)
The virus is maintained in an enzootic cycle between mosquitoes and amplifying vertebrate hosts, primarily pigs and wading birds.(1,2)
Where does JE occur?
JE is endemic in 25 countries across Asia and parts of the western Pacific.(3)
The area of transmission of JE virus has expanded in recent years, most notably in Australia, with widespread areas of transmission detected during 2021–2022.(2) The risk areas in Australia include the following regions: Outer Torres Strait Islands, Tiwi Islands, and some areas of the mainland (parts of New South Wales, Victoria, Queensland, South Australia, and the Northern Territory).(3)
Transmission of the virus through mosquitoes occurs in rural agricultural areas, often associated with rice cultivation and flood irrigation, but also in urban centers.(2) In temperate areas of Asia, transmission is seasonal, and human disease usually peaks in summer and fall.(2) In the subtropics and tropics, seasonal transmission varies with monsoon rains and irrigation practices and may be prolonged or even occur year-round.(2)
Who is at risk of contracting JE?
For most travelers to Asia, the risk for JE is extremely low but varies based on their destination, duration of travel, season, and activities.(2)
However, expatriates and travelers who stay for prolonged periods in rural areas with active JE virus transmission might be at similar risk as the pediatric resident
population.(2)
Travelers on even brief trips might be at increased risk if they have extensive outdoor or nighttime exposure in rural areas during periods of active transmission.(2)
What are the symptoms and lasting effects of JE?
Most people infected with JE are asymptomatic or only have mild symptoms.(2) Acute encephalitis is the most recognized clinical manifestation of JE virus infection.(2) The incubation period is 5–15 days.(2)
Illness usually begins with sudden onset of fever, headache, and vomiting.(2) Mental status changes, focal neurologic deficits, generalized weakness, and movement disorders may develop over the next few days.(2) The classical description of JE includes a parkinsonian syndrome.(2) Acute flaccid paralysis has also been associated with JEV infection. Seizures are common, especially among children.(2)
The case-fatality ratio is approximately 20%–30%.(2)
Among survivors, 30%–50% have serious neurologic, cognitive, or psychiatric sequelae.(2)
How can JE be treated?
There is currently no specific antiviral treatment available for JE.(1,2,4)
Treatment is supportive to relieve symptoms and stabilize the patient.(1,2,4)
To reduce the risk for JE, all travelers to Japanese encephalitis-endemic areas should take precautions to avoid mosquito bites.(1,2,4)
JE vaccines are available to prevent the disease.(1,2)
References
- WHO. Fact sheet. Japanese Encephalitis. August 2024. Online available: https://www.who.int/news-room/fact-sheets/detail/japanese-encephalitis (last accessed February 2026)
- CDC. Yellow Book. Japanese Encephalitis. April 23,2025. Online available: https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/japanese-encephalitis.html (last accessed February 2026)
- CDC. Areas at Risk for Japanese Encephalitis. Feb 4, 2026. Online available:
https://www.cdc.gov/japanese-encephalitis/datamaps/?
CDC_AAref_Val=https://www.cdc.gov/japaneseencephalitis/maps/ (last accessed February
2026) - CDC. Japanese Encephalitis Virus. Symptoms, Diagnosis, and Treatment. November 19, 2025. Online available: https://www.cdc.gov/japanese-encephalitis/symptoms-diagnosis-treatment/index.html (last accessed February 2026)
- BMSGPK. Impfplan Osterreich 2025/2026, Version 1.1 vom 10. Oktober 2025. Online available:
https://www.sozialministerium.gv.at/Themen/Gesundheit/Impfen/impfplan.html (last accessed
February 2026)

